Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2015-07-20

FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)

View source ↗

Summary

FDA approves a supplemental application for AKYNZEO (netupitant and palonosetron) to update its labeling for the prevention of chemotherapy-induced nausea and v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Akynzeo (netupitant/palonosetron)

Snippet

SUPPL AP for AKYNZEO (NETUPITANT AND PALONOSETRON)